{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:46:33Z","timestamp":1788921993011,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.cllc.2024.09.005","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T15:52:57Z","timestamp":1726933977000},"page":"723-731.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM)"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-6855","authenticated-orcid":false,"given":"Diego","family":"Enrico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Elias","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Soledad","family":"Tissera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"Tsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Pupareli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delfina Peralta","family":"Tanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Waisberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manglio","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s","family":"Minatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Picon","family":"Rafael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Basbus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Lupinacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Kaen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Bluthgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Castagneris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda P\u00eda","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Scocimarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Florencia","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Perfetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Levit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Galvez-Nino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Mas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo","family":"Zuluaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas","family":"Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Corrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Samtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Arrieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cllc.2024.09.005_bib0001","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/carcin\/bgz004","article-title":"Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database","volume":"40","author":"Van Gerwen","year":"2019","journal-title":"Carcinogenesis"},{"issue":"11","key":"10.1016\/j.cllc.2024.09.005_bib0002","first-page":"1841","article-title":"Malignant pleural mesothelioma: a population-based study of survival","volume":"5","author":"Milano","year":"2010","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"24","key":"10.1016\/j.cllc.2024.09.005_bib0003","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.3390\/cancers15245787","article-title":"Current state-of-the-art therapy for malignant pleural mesothelioma and future options centered on immunotherapy","volume":"15","author":"Cedres","year":"2023","journal-title":"Cancers"},{"issue":"10026","key":"10.1016\/j.cllc.2024.09.005_bib0004","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"The Lancet"},{"issue":"10272","key":"10.1016\/j.cllc.2024.09.005_bib0005","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.cllc.2024.09.005_bib0006","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2024.09.005_bib0007","unstructured":"FDA. FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma. 2021 Accessed May 4, 2024; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma."},{"key":"10.1016\/j.cllc.2024.09.005_bib0008","unstructured":"ESMO. EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab. Accessed May 4, 2024;Available from: https:\/\/www.esmo.org\/oncology-news\/ema-recommends-extension-of-therapeutic-indications-for-nivolumab-and-ipilimumab."},{"key":"10.1016\/j.cllc.2024.09.005_bib0009","doi-asserted-by":"crossref","first-page":"LBA8505","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA8505","article-title":"IND227 phase III (P3) study of cisplatin\/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial","volume":"41","author":"Chu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17 Suppl","key":"10.1016\/j.cllc.2024.09.005_bib0010","article-title":"BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)\u2014Results from the ETOP 13-18 trial","volume":"42","author":"Felip","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2024.09.005_bib0011","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1093\/oncolo\/oyac114","article-title":"Strengths, and limitations of real-world evidence in oncology: a Canadian review and perspective","volume":"27","author":"Rationale","year":"2022","journal-title":"The Oncologist"},{"issue":"9","key":"10.1016\/j.cllc.2024.09.005_bib0012","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1200\/JCO.23.02399","article-title":"Real-world database studies in oncology: a call for standards","volume":"42","author":"Ramsey","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.cllc.2024.09.005_bib0013","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2023.03.013","article-title":"Defining the role of real-world data in cancer clinical research: the position of the European Organisation for research and treatment of cancer","volume":"186","author":"Saesen","year":"2023","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.cllc.2024.09.005_bib0014","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1634\/theoncologist.2019-0647","article-title":"Real-world evidence in oncology: opportunities and limitations","volume":"25","author":"Di Maio","year":"2020","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.cllc.2024.09.005_bib0015","first-page":"1012","article-title":"Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"3","key":"10.1016\/j.cllc.2024.09.005_bib0016","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.09.005_bib0017","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2005.07.050","article-title":"Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials","volume":"23","author":"Fennell","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.cllc.2024.09.005_bib0018","article-title":"FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type","volume":"37","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2024.09.005_bib0019","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1093\/annonc\/mdx414","article-title":"Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy","volume":"28","author":"McCoach","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.cllc.2024.09.005_bib0020","doi-asserted-by":"crossref","first-page":"v382","DOI":"10.1093\/annonc\/mdz249.046","article-title":"Association between depth of response and overall survival: exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214","volume":"30","author":"Gr\u00fcnwald","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2024.09.005_bib0021","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time bias in observational studies","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.cllc.2024.09.005_bib0022","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma","volume":"145","author":"Indini","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.09.005_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.cllc.2024.09.005_bib0024","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s10147-023-02406-x","article-title":"Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis","volume":"28","author":"Washino","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.09.005_bib0025","doi-asserted-by":"crossref","first-page":"8536","DOI":"10.1200\/JCO.2023.41.16_suppl.8536","article-title":"Real-life efficacy of nivolumab plus ipilimumab combination in untreated, unresectable malignant pleural mesotheliomas: result of French early access program\u2014MESOIMMUNE \u2013 GFPC 04-2021","volume":"41","author":"Bylicki","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.09.005_bib0026","article-title":"Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma","volume":"187","author":"Dumoulin","year":"2024","journal-title":"Lung Cancer Amst Neth"},{"issue":"4","key":"10.1016\/j.cllc.2024.09.005_bib0027","first-page":"636","article-title":"Brief report: real-world toxicity and survival of combination immunotherapy in pleural mesothelioma-RIOMeso","volume":"19","author":"McNamee","year":"2024","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424002006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424002006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T23:47:41Z","timestamp":1732319261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730424002006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1525730424002006"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2024.09.005","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2024.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}